Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Lesueur P, Lequesne J, Grellard JM, Dugué A, Coquan E, Brachet PE, Geffrelot J, Kao W, Emery E, Berro DH, Castera L, Goardon N, Lacroix J, Lange M, Capel A, Leconte A, Andre B, Léger A, Lelaidier A, Clarisse B, Stefan D. Lesueur P, et al. Among authors: dugue a. BMC Cancer. 2019 Mar 4;19(1):198. doi: 10.1186/s12885-019-5413-y. BMC Cancer. 2019. PMID: 30832617 Free PMC article.
O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E, Levallet G, Dugué AE, Vital A, Diebold MD, Menei P, Colin P, Peruzzy P, Emery E, Bernaudin M, Chapon F, Guillamo JS. Lechapt-Zalcman E, et al. Among authors: dugue ae. Cancer. 2012 Sep 15;118(18):4545-54. doi: 10.1002/cncr.27441. Epub 2012 Feb 22. Cancer. 2012. PMID: 22359215 Free article.
Optimisation of chemotherapy prescription and preparation in an ambulatory unit: Validation of the OPTIMA program.
Dos Santos M, Lequesne J, Dugué AE, Grellard JM, Ory C, Jaffré S, Lavergne K, Lelaidier A, Laroche L, Divanon F, Delcambre C, Galais MP, Clarisse B, Faveyrial A. Dos Santos M, et al. Among authors: dugue ae. Eur J Cancer Care (Engl). 2019 May;28(3):e13015. doi: 10.1111/ecc.13015. Epub 2019 Feb 20. Eur J Cancer Care (Engl). 2019. PMID: 30790365
How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study.
Vanbockstael J, Coquan E, Gouerant S, Allouache D, Faveyrial A, Noal S, Delcambre C, Galais MP, Héron JF, Lefebvre AC, Sevin E, Hrab I, Polycarpe F, André M, Kaluzinski L, Gervais R, Gunzer K, Vié B, Saucier G, Lemenand N, Grellard JM, Clarisse B, Dugué AE, Joly F. Vanbockstael J, et al. Among authors: dugue ae. Support Care Cancer. 2016 Mar;24(3):1131-8. doi: 10.1007/s00520-015-2882-7. Epub 2015 Aug 14. Support Care Cancer. 2016. PMID: 26268784
Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Lheureux S, N'Diaye M, Blanc-Fournier C, Dugué AE, Clarisse B, Dutoit S, Giffard F, Abeilard E, Briand M, Labiche A, Grellard JM, Crouet H, Martin S, Joly F, Poulain L. Lheureux S, et al. Among authors: dugue ae. Int J Cancer. 2015 Mar 1;136(5):E340-50. doi: 10.1002/ijc.29104. Epub 2014 Aug 8. Int J Cancer. 2015. PMID: 25066666
REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours.
Lévy C, Allouache D, Lacroix J, Dugué AE, Supiot S, Campone M, Mahe M, Kichou S, Leheurteur M, Hanzen C, Dieras V, Kirova Y, Campana F, Le Rhun E, Gras L, Bachelot T, Sunyach MP, Hrab I, Geffrelot J, Gunzer K, Constans JM, Grellard JM, Clarisse B, Paoletti X. Lévy C, et al. Among authors: dugue ae. Ann Oncol. 2014 Dec;25(12):2351-2356. doi: 10.1093/annonc/mdu465. Epub 2014 Oct 1. Ann Oncol. 2014. PMID: 25274615 Free article. Clinical Trial.
BRCA1 allele-specific expression in genetic predisposed breast/ovarian cancer.
Jamard E, Volard B, Dugué AE, Legros A, Leconte A, Clarisse B, Davy G, Polycarpe F, Dugast C, Abadie C, Frebourg T, Tinat J, Tennevet I, Layet V, Joly F, Castéra L, Berthet P, Vaur D, Krieger S. Jamard E, et al. Among authors: dugue ae. Fam Cancer. 2017 Apr;16(2):167-171. doi: 10.1007/s10689-016-9940-2. Fam Cancer. 2017. PMID: 27783335 Clinical Trial.
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.
Sassier M, Dugué AE, Clarisse B, Lesueur P, Avrillon V, Bizieux-Thaminy A, Auliac JB, Kaluzinski L, Tillon J, Robinet G, Le Caer H, Monnet I, Madroszyk A, Boza G, Falchero L, Fournel P, Egenod T, Toffart AC, Leiber N, Do P, Gervais R. Sassier M, et al. Among authors: dugue ae. Lung Cancer. 2015 Aug;89(2):161-6. doi: 10.1016/j.lungcan.2015.05.005. Epub 2015 May 15. Lung Cancer. 2015. PMID: 26037036
46 results